Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23216537 | 0.80 | DRD2 (0.46) | FTOHPGDTSHRHSD17B10SLC6A2 | |
| SCHEMBL29768482 | 0.80 | DRD2 (0.46) | FTOHPGDTSHRHSD17B10SLC6A2 | |
| SCHEMBL18272148 | 0.77 | FTO (0.39) | FTOHPGDTSHRHSD17B10SLC6A4 | |
| SCHEMBL23216871 | 0.76 | SLC6A2 (0.52) | FTOHPGDTSHRHSD17B10SLC6A2 | |
| SCHEMBL23216405 | 0.76 | SIGMAR1 (0.41) | FTOSLC6A2SLC6A4DRD2HTR2A | |
| SCHEMBL29768369 | 0.76 | SIGMAR1 (0.41) | FTOSLC6A2SLC6A4DRD2HTR2A | |
| SCHEMBL23216631 | 0.75 | OPRM1 (0.33) | FTOHPGDTSHRHSD17B10SLC6A2 | |
| SCHEMBL29768379 | 0.75 | OPRM1 (0.33) | FTOHPGDTSHRHSD17B10SLC6A2 | |
| SCHEMBL655089 | 0.70 | GRIN1 (0.42) | SLC6A2SLC6A4DRD2HTR2AHTR2C | |
| SCHEMBL23333094 | 0.70 | OPRM1 (0.38) | SLC6A2SLC6A4HTR2AHTR2CSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-4041407-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114746151-A | Aryl heterocyclic compounds as Kv1.3 potassium Shaker channel blockers | D·E·萧尔研究有限责任公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021071802-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071802-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNA3, KCNH2, KCNJ2 | FTO 2139/4885HPGD 2935/4885TSHR 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.